Opportunity
Simpler Grants.gov #RFA-DK-27-116
NIH NIDDK IBD Genetics Consortium Genomic Research Centers Funding Opportunity
Buyer
National Institutes of Health
Posted
October 04, 2023
Respond By
November 01, 2026
Identifier
RFA-DK-27-116
NAICS
541714, 541715
This opportunity is a forecasted funding announcement from the National Institutes of Health (NIH), specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to support the Inflammatory Bowel Disease Genetics Consortium (IBDGC). - Government Buyer: - National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - No specific Original Equipment Manufacturers (OEMs) or commercial vendors are named in this opportunity. - Products/Services Requested: - Up to seven Genomic Research Centers to conduct research on genetic risk loci and biological mechanisms of Inflammatory Bowel Disease (IBD) - Activities include participant enrollment, molecular analysis of biospecimens, and advanced bioinformatics/computational analyses - Unique/Notable Requirements: - Integration of clinical, genetic, and environmental data - Development of new predictors for disease outcomes - Emphasis on improving precision medicine for IBD patients - Funding Details: - Program funding of $6,400,000 - Up to nine awards anticipated - Cooperative agreement mechanism to support research collaboration - No specific products, part numbers, or quantities are listed, as this is a research funding opportunity rather than a procurement of goods.
Description
The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) seeks to continue the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) to advance research on genetic risk loci and biological mechanisms of IBD. The consortium aims to leverage patient cohorts, biospecimens, and data science to understand genetic, clinical, and environmental factors in disease development and progression. The goal is to develop new predictors of disease outcomes to improve medical management and precision medicine for IBD patients. The IBDGC may include up to 7 Genomic Research Centers focusing on participant enrollment, molecular analysis, and computational analyses.